Mellow Hope (HTDS) Delivers First Batch of BIOVAC-FLU Samples to India

pm EST
SHENZHEN, CHINA--(Marketwire - 11/19/10) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) (www.htdsmedical.com) subsidiary Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) has delivered its first BIOVAC-FLU samples to India.

Mellow Hope (www.mellowhope.com/en/main.asp), the biggest exporter of biological vaccines in China, has delivered a batch of Influenza virus vaccines, Inactivated (Split) (BIOVAC-FLU) to a company in India for sample analysis before beginning the new purchase order. The company expects to finalize the sample analysis within one month. After that a new purchase order will be signed between Mellow Hope and the partner in India. That is the first batch of BIOVAC-FLU exported to India in 2010.

Mellow Hope is pleased with this agreement and hopes that this will provide new opportunities for growth.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this quarterly report constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.